Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Tempus Tempus Receives U.S. FDA 510(k) Clearance for Tempus ECG-AF, an AI-based Algorithm that Identifies Patients at Increased Risk of AFib June 26, 2024 From Tempus Via Business Wire Tickers TEM Tempus Announces Collaboration with United Therapeutics to Study Use of AI to Detect Patients at Risk for Pulmonary Hypertension June 25, 2024 From Tempus Via Business Wire Tempus Introduces New HER2 & FOLR1 Testing Solutions to Support Personalized Patient Care June 02, 2024 From Tempus Via Business Wire Tempus Announces Expansion of Collaboration with AstraZeneca to Leverage Tempus Next to Support Guideline-directed Biomarker Testing in NSCLC June 01, 2024 From Tempus Via Business Wire Tempus Announces the Clinical Launch of its MRD Testing Portfolio May 31, 2024 From Tempus Via Business Wire Tempus Introduces its AI-enabled Care Pathway Intelligence Platform, Tempus Next April 16, 2024 From Tempus Via Business Wire Tempus Releases New Data at AACR Showcasing Ways to Analyze Multimodal Data to Highlight Potential Therapeutic Routes for HER2-Directed Antibody-Drug Conjugates in Several Tumor Types April 08, 2024 From Tempus Via Business Wire Tempus Introduces Workspaces into its Lens Data Analytics Platform April 06, 2024 From Tempus Via Business Wire Tempus Announces 18 Abstracts Accepted For Presentation at the American Association for Cancer Research Annual Meeting 2024 April 05, 2024 From Tempus Via Business Wire Tempus Contributes De-Identified Cancer Data to Planned Data Enclave March 14, 2024 From Tempus Via Business Wire Tempus Expanding Access to its Next-Generation Sequencing Tests as an In-Network Provider for Cigna February 21, 2024 From Tempus Via Business Wire Tempus Introduces AI-enabled Assistant, Tempus One, Into Lens Data Analytics Platform to Accelerate Research February 02, 2024 From Tempus Via Business Wire Tempus is Now an In-Network Provider for Humana, Expanding Access to its Next-Generation Sequencing Tests January 24, 2024 From Tempus Via Business Wire Tempus Introduces xM to Assess Minimal Residual Disease (MRD) in Patients with Colorectal Cancer (CRC) for Research Use Only January 18, 2024 From Tempus Via Business Wire Tempus Announces Medicare Coverage for Tempus|xT Across Solid Tumor and Hematologic Malignancies November 15, 2023 From Tempus Via Business Wire Tempus Announces Research Collaboration with Bristol Myers Squibb to Apply Multimodal AI Approaches November 08, 2023 From Tempus Via Business Wire Tempus Announces New ctDNA Assay, xF Monitor November 03, 2023 From Tempus Via Business Wire FDA Grants Breakthrough Device Designation To Tempus’ HLA-LOH Companion Diagnostic Test August 15, 2023 From Tempus Via Business Wire Tempus Announces the GEMINI Non-Small Cell Lung Cancer Study July 12, 2023 From Tempus Via Business Wire Tempus Announces Companion Diagnostic Collaboration with TScan Therapeutics July 06, 2023 From Tempus Via Business Wire Tempus Announces Broad Launch of Tempus One June 01, 2023 From Tempus Via Business Wire Tempus Announces Dr. Ned Sharpless as a Senior Strategic Advisor May 10, 2023 From Tempus Via Business Wire Tempus Receives U.S. FDA Approval for xT CDx, a NGS-Based In Vitro Diagnostic Device May 01, 2023 From Tempus Via Business Wire Tempus Announces New Strategic Collaboration with Pfizer to Advance Oncology Therapeutic Development February 28, 2023 From Tempus Via Business Wire Tempus Announces Prospective Study for Biomarker Discovery in Small Cell Lung Cancer January 05, 2023 From Tempus Via Business Wire Tickers AZN Tempus Launches First Cardiology Prospective Study for Its AI-Enabled Predictive Tests November 03, 2022 From Tempus Via Business Wire Tempus Announces Real-World Data-Driven Program to Accelerate Precision Oncology Research October 27, 2022 From Tempus Via Business Wire Tempus Announces Companion Diagnostic Collaboration with Kartos Therapeutics October 06, 2022 From Tempus Via Business Wire Tempus Announces Three Abstracts Accepted For Presentation at the European Society for Medical Oncology Congress 2022 September 09, 2022 From Tempus Via Business Wire Tempus Announces Sequencing Collaboration With Lilly to Expand Access to Genomic Testing June 09, 2022 From Tempus Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.